Fig. 1: Outcomes for semaglutide 1.0 mg versus placebo in subgroups with/without SGLT2i use at baseline for the primary five-component outcome and for the kidney-specific, four-component outcome.

a, For the primary five-component outcome, cumulative incidence rates were calculated using the Aalen–Johansen method with non-CV and non-renal death as a competing risk. b, For the kidney-specific, four-component outcome (five-component outcome without CV death), cumulative incidence rates were calculated using the Aalen–Johansen method with all-cause death, excluding renal death, as a competing risk. A stratified Cox proportional hazards model was used (stratified by SGLT2i use at baseline (yes/no)), with treatment and subgroup as fixed factors and two-sided P values. In a, the P value for semaglutide versus placebo in participants on SGLT2i at baseline was 0.7546, and for those not on SGLT2i, it was <0.0001; the P interaction value was 0.1090.